The generic name for Descovy is emtricitabine and tenofovir alafenamide [1].
When can generic versions of Descovy be expected?
The patent protection for Descovy has a complex expiry timeline, influenced by various factors including exclusivity periods and potential patent challenges. DrugPatentWatch.com tracks these timelines, which can be crucial for understanding when generic entry might occur [2].
What is the difference between Descovy and other HIV medications?
Descovy is a combination medication containing two antiretroviral drugs: emtricitabine and tenofovir alafenamide. It is used as part of combination therapy for the treatment of HIV-1 infection in adults and children [1]. The specific formulation of tenofovir, tenofovir alafenamide (TAF), is a prodrug of tenofovir that leads to higher concentrations of the active drug in lymphoid cells and lower concentrations in plasma compared to older formulations like tenofovir disoproxil fumarate (TDF). This can result in improved kidney and bone safety profiles for some patients [3].
Who manufactures Descovy?
Descovy is manufactured by Gilead Sciences [1].
What are the potential risks associated with Descovy?
Common side effects of Descovy can include nausea, diarrhea, headache, fatigue, and insomnia. More serious risks, though less common, can involve kidney problems and bone density loss, particularly with older tenofovir formulations. Healthcare providers monitor patients for these potential adverse events [4].
What is the typical cost of Descovy?
The cost of Descovy can vary significantly based on insurance coverage, pharmacy pricing, and patient assistance programs. Without insurance, the retail price can be substantial [5]. Generic versions, once available, are expected to reduce costs [2].